Showing 1 - 3 results of 3 for search 'Alexander Paliege', query time: 0.01s Refine Results
  1. 1
    WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL

    WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

    Published 2024-04-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL

    WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL by Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Jonathan Barratt

    Published 2024-04-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL

    WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

    Published 2024-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: